Skip to main content

Table 1 Summary of intake data by receptor status and antioestrogenic drug prescription

From: Food choice and phytoestrogen consumption in women previously treated for postmenopausal breast cancer

Total phytoestrogen intake (μg/1,000 kcal) (n = 316) n First quartile Second quartile Third quartile Fourth quartile
   Receptor status      
Mean 8,388    ER-negative 42 11 (14%) 11 (14%) 13 (16%) 7 (9%)
Range 126 to 77,703    ER-positive 182 40 (51%) 42 (53%) 48 (61%) 52 (66%)
Quartile ranges      Not available 92 28 (35%) 26 (33%) 18 (23%) 20 (25%)
   First quartile <3,817 Antioestrogenic drugs      
   Second quartile 3,817 to 6,798    No prescription 109 30 (38%) 30 (38%) 25(32%) 24 (30%)
   Third quartile 6,799 to 10,255    Tamoxifen or arimidexa 200 47 (59%) 47 (59%) 52 (65%) 54 (68%)
   Fourth quartile >10,255    Other/missing 7 2 (3%) 2 (3%) 2 (3%) 1 (2%)
  1. aAstraZeneca, London, UK.